Professional Documents
Culture Documents
Curt R. Hartman
President & Chief Executive Officer
Luke A. Pomilio
Chief Financial Officer
2
Company Snapshot
Company Overview Global Presence
n Founded in 1970 in Utica, NY, CONMED is a global medical technology organization with n Direct sales to 17 countries and indirect
~3,400 employees and sales across six continents sales to more than 100 countries
3
Q3 2016 Results and 2016 Guidance
Q3 2016
Comments on Q3 2016
Global General Surgery sales grew 29.2% as reported, 30.6% in constant currency, and
4.2% organically in constant currency.
Domestic sales growth driven by strong performance of General Surgery, partially offset by
declines in Orthopedics and Visualization. Endoscopic Technology delivered its third
consecutive quarter of mid-single-digit or greater growth.
Internationally, all three reporting businesses posted constant currency organic growth for
the second consecutive quarter.
1Excludes the after-tax costs of special items including acquisitions, restructuring, the gain on the sale of the Companys facility in Centennial, Colorado,
and debt refinancing, as well as amortization of intangible assets, net of tax.
4
Orthopedics Overview
Description Global Market/Key Competitors
Devices for repair of soft tissue injuries in $4.4 to $4.6 Billion
joints, particularly the knee and shoulder Arthrex
Sports Medicine DePuy Mitek (J&J)
Smith & Nephew
Stryker
5
General Surgery Overview
Description Global Market/Key Competitors
A platform of devices and accessories to $1.4 to $1.6 Billion
create and enter the surgical working Ethicon (J&J) Medtronic (Covidien)
space in minimally invasive procedures Applied Medical
Access Stryker
Karl Storz
Olympus
6
Growth Through People and Products
2015 2016
7
Leadership Team
COMMERCIAL FUNCTIONAL
Years at Years in Years at Years in
Executive Title CONMED Industry Executive Title CONMED Industry
Curt President & 2 26 Luke EVP & CFO 21 21
Hartman CEO Pomilio
8
CONMEDs Innovation Journey
Project budgets and timetables lacked Strategic planning process completed; new
accountability commercial, marketing, and R&D leaders own
product roadmap strategy and execution
Market acceptance of released products was
limited R&D departments restructured under new leader
10
Inorganic Growth Complements Organic Pipeline
AirSeal is the most technologically advanced and only integrated access management system
for robotic and laparoscopic surgery, enabling numerous clinical benefits with the low impact
laparoscopy approach
11
AirSeal 2016 Execution (as of Q3)
Original Target Results
On Track to
Sales $55M to $60M
Exceed
Cost $15M
On Track to
Synergies Realize
12
AirSeal Domestic and Global Market
Domestic Procedure Market
Robotic Surgery (2014) ~450,000
International Sales represent 47% of consolidated sales. International business split: Direct 2/3, Export 1/3
14
Domestic Commercial Progress
Domestic Orthopedics Sales Growth
Mixed performance
Procedure specific consistently positive
Arthroscopy Enabling Devices (resection, fluid)
challenged; EDGE system should help stabilize
Capital results mixed
Focus on the MTF opportunity
Focus on sales execution and sales channel
Account access and contract strategy in progress
New products critical to success
Domestic Orthopedics represents 23% of consolidated sales
15
CONMED vs Market Growth Rates
16
Financial Goal - EBITDA
17
2017 Priorities
18
Closing Thoughts
19
Destination of Choice
20